Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
IN8bio halts phase 2 trial, lays off half of workforce
The biotech is shifting focus to INB-100, an allogeneic cell therapy being tested in acute myeloid leukemia patients receiving stem cell transplants.
Darren Incorvaia
Sep 5, 2024 4:30am
Repare lays off 25% of staff as biotech halts preclinical R&D
Aug 29, 2024 6:36am
Merck bags one Kelun ADC for $37.5M, boots out another asset
Aug 20, 2024 6:43am
Metagenomi axes ALS program after seeing Biogen and Ionis flop
Aug 14, 2024 9:20am
Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect
Aug 7, 2024 7:00am
Relay loses interest in SHP2 inhibitor after Genentech leaves
Aug 7, 2024 6:00am